Dr. Akansha Bhargava is the Chief Development Officer at RIGImmune Inc. Previously Akansha held a position as a Blavatnik Fellow at Yale University in the Office of Cooperative Research where she advised early-stage life science technology startups across the biotech, digital health, and med tech space to further research commercialization and new venture formation. Prior to that, she served as the Director of Clinical Development at Soleno Therapeutics a biotech company based in Redwood City, CA developing therapeutics for rare diseases. Dr. Bhargava completed her B.S. in Genetics from the University of Wisconsin- Madison, M.S. in Biotechnology with a concentration in Biodefense from Johns Hopkins University and holds a medical degree from the Royal College of Surgeons in Ireland.